, Volume 38, Issue 12, pp 1162-1166

Increased expression of MUC1 in advanced pancreatic cancer

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Background

Methods

Tissue specimens obtained from 70 patients with invasive ductal carcinoma of the pancreas, in pTNM stage III or IV, were immunostained with the anti-MUC1 monoclonal antibody DF3. The results of immunostaining were determined to be positive when more than 50% of the total cancer cells were positively stained. Association of the expression of the DF3 epitope with clinicopathological parameters or patients’ survival was statistically evaluated.

Results

The incidence of positivity of MUC1 expression was 55.7% (39/70) and this incidence was significantly higher in pTNM stage IV than in stage III (odds ratio [OR], 4.015; 95% confidence interval [CI], 1.459–11.0541; P = 0.0076). As there was a clear difference in overall survival between pTNM stages III and IV (P = 0.0016), the effect of MUC1 expression on survival was separately evaluated in each stage. It was shown that the expression of MUC1 was associated with unfavorable overall survival in stage IV (P = 0.0197).

Conclusions

Our data suggest that the expression of MUC1 may be related to the progression of pancreatic cancer.